Illumina, Inc. $ILMN Stock Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 15.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 226,745 shares of the life sciences company’s stock after selling 41,836 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Illumina were worth $61,785,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Illumina in the 3rd quarter valued at $269,000. International Assets Investment Management LLC grew its holdings in shares of Illumina by 111.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,091 shares of the life sciences company’s stock valued at $290,000 after purchasing an additional 575 shares during the last quarter. Heritage Family Offices LLP purchased a new position in Illumina in the 3rd quarter worth $209,000. Alta Advisers Ltd bought a new stake in Illumina in the third quarter worth $303,000. Finally, Kestra Advisory Services LLC lifted its stake in Illumina by 21.4% in the third quarter. Kestra Advisory Services LLC now owns 5,416 shares of the life sciences company’s stock worth $1,482,000 after purchasing an additional 953 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Keith Meister sold 299,336 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $217.96, for a total value of $65,243,274.56. Following the completion of the sale, the director directly owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. This trade represents a 17.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 1,601,541 shares of company stock valued at $354,755,291. 2.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Weiss Ratings upgraded Illumina from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, November 2nd. JPMorgan Chase & Co. lowered their target price on Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Royal Bank Of Canada increased their target price on Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Finally, Evercore restated an “underperform” rating on shares of Illumina in a research report on Friday, October 30th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $244.24.

Illumina Price Performance

Shares of Illumina stock opened at $220.78 on Tuesday. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The company has a market cap of $33.38 billion, a PE ratio of 38.00, a P/E/G ratio of 3.08 and a beta of 1.46. The business has a 50 day moving average of $249.25 and a 200 day moving average of $178.46. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.26. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.34 earnings per share. As a group, equities research analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current year.

About Illumina

Illumina, Inc develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data.

The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers internationally.